Science

Genomics

We work with more than 60 organisations across 19 countries—and growing—to ensure our data increasingly represents diverse and understudied communities around the world. Today, 40% of the genomic data that fuels our R&D comes from people of non-European ancestry, enabling discovery and development that can benefit a broader range of people.

Insights from these data are woven throughout our R&D, helping us uncover new biology, identify potentially promising drug targets, speed up biomarker discovery, and guide clinical development and late‑stage decision-making.

Clinical trials

We aim to build more representative clinical trials that better reflect the patient communities we serve to help improve access to innovative therapies and ensure our medicines are effective across different populations.

To support this, we’re strengthening clinical trial site capabilities in middle-income countries and increasing recruitment of underserved rural patients in high-income countries.

We’ve also expanded rare disease trials to more countries to better reflect the unique needs of this patient group and the diversity of the communities is unique patient diversity and need.

Open innovation

Through our Open Innovation programme, we openly share molecules, data and scientific expertise with academic researchers and start-ups; we currently have multiple ongoing clinical trials, over 150 ongoing preclinical studies and collaborative research projects. We are also participating in more than 20 public-private partnership projects aimed at addressing key scientific challenges.